Technology Bundle ID
NCI-E-151-2017

Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders

Applications
Therapeutics
Co-Inventors
Christopher Ramsden (NIA)
Gregory Keyes (NIA)
Development Status
Pre-clinical (in vivo)
ICs
NIA

The discovery and selection of suitable compounds for the treatment and prevention of autoimmune, inflammatory, and pain disorders is a significant challenge. Researchers at National Institute of Aging (NIA) mitigated this issue. They discovered and synthesized numerous novel fatty acid derivatives (novel small molecules) that may ameliorate these conditions and provide treatment options for these disorders. In a relevant rat model, the fatty acid derivatives developed by NIA demonstrated:

  • increased activity
  • lower toxicity
  • greater stability
  • longer half-life

These beneficial results favorably compare to prior agents utilized for treating inflammation, autoimmune disorders, and/or pain. Certain of the disclosed fatty acid derivatives are capable of readily crossing the blood-brain barrier – providing an advantage specifically with respect to certain pain disorders.  

NIA is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize fatty acid derivatives.  In addition, NIA is open to collaborative research relationships (such as under a CRADA) whereby resources such as intellectual property can be pooled and applied to the development of therapies with respect to a wide variety of autoimmune and inflammatory and pain-related conditions.  In addition, NIA is open to a wide variety of licensing arrangements with respect to these technologies.

Commercial Applications

Therapies to treat:

  • Autoimmune disorders
  • Inflammation
  • Pain-related disorders
  • Itching and/or skin disorders
Competitive Advantages
  • Ability to readily cross the blood-brain barrier
  • Increased activity, lower toxicity, greater stability, and longer half-life in a relevant proof-of-concept rat model compared with drugs currently available for treating inflammation, autoimmune disorders, and/or pain
  • Substantial intellectual property life cycle: e.g., patents if issued likely will expire no earlier than 2038
  • Proof-of-concept in rat model

Request More Info

Licensing Contact: